CN115884810B - 作为il-17调节剂的咪唑并哒嗪 - Google Patents

作为il-17调节剂的咪唑并哒嗪 Download PDF

Info

Publication number
CN115884810B
CN115884810B CN202180047160.XA CN202180047160A CN115884810B CN 115884810 B CN115884810 B CN 115884810B CN 202180047160 A CN202180047160 A CN 202180047160A CN 115884810 B CN115884810 B CN 115884810B
Authority
CN
China
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
compound
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180047160.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN115884810A (zh
Inventor
D·贝海纳
C·德克胡特
A·罗维拉
S·戈德堡
D·库默
J·基思
C·伍兹
T·罗雷尔
V·坦尼斯
C·马丁
S·梅杜纳
S·麦克卡弗
A·瓦尔德斯
S·洛斯科特
薛晓华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN115884810A publication Critical patent/CN115884810A/zh
Application granted granted Critical
Publication of CN115884810B publication Critical patent/CN115884810B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Lubricants (AREA)
  • Fats And Perfumes (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202180047160.XA 2020-04-30 2021-04-28 作为il-17调节剂的咪唑并哒嗪 Active CN115884810B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063017682P 2020-04-30 2020-04-30
US63/017682 2020-04-30
PCT/US2021/029641 WO2021222404A1 (en) 2020-04-30 2021-04-28 Imidazopyridazines as modulators of il-17

Publications (2)

Publication Number Publication Date
CN115884810A CN115884810A (zh) 2023-03-31
CN115884810B true CN115884810B (zh) 2025-01-17

Family

ID=76197556

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180047160.XA Active CN115884810B (zh) 2020-04-30 2021-04-28 作为il-17调节剂的咪唑并哒嗪

Country Status (20)

Country Link
US (3) US11691979B2 (https=)
EP (1) EP4143195B1 (https=)
JP (1) JP7664947B2 (https=)
KR (1) KR20230019507A (https=)
CN (1) CN115884810B (https=)
AR (1) AR121959A1 (https=)
AU (1) AU2021264528A1 (https=)
BR (1) BR112022021962A2 (https=)
CA (1) CA3181676A1 (https=)
CO (1) CO2022017072A2 (https=)
EC (1) ECSP22091485A (https=)
ES (1) ES3036330T3 (https=)
IL (1) IL297705A (https=)
JO (1) JOP20220284A1 (https=)
MX (1) MX2022013647A (https=)
PE (1) PE20230469A1 (https=)
TW (1) TWI874645B (https=)
UY (1) UY39188A (https=)
WO (1) WO2021222404A1 (https=)
ZA (1) ZA202212967B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201909190D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
PE20230469A1 (es) * 2020-04-30 2023-03-14 Janssen Pharmaceutica Nv Imidazopiridazinas como moduladores de il-17
CN115867348B (zh) 2020-04-30 2025-05-06 詹森药业有限公司 作为il-17调节剂的咪唑并嘧啶
EP4259631A1 (en) * 2020-12-14 2023-10-18 UCB Biopharma SRL Imidazopyridazine derivatives as il-17 modulators
WO2023025783A1 (en) 2021-08-23 2023-03-02 Leo Pharma A/S Small molecule modulators of il-17
KR20240082371A (ko) 2021-09-27 2024-06-10 얀센 파마슈티카 엔브이 이미다조피리다진 il-17 억제제 화합물
IL311751A (en) 2021-09-27 2024-05-01 Janssen Pharmaceutica Nv IL-17 imidazopyridazine inhibitory compounds
WO2023111181A1 (en) 2021-12-16 2023-06-22 Leo Pharma A/S Small molecule modulators of il-17
CN118580191A (zh) * 2022-01-28 2024-09-03 和记黄埔医药（上海）有限公司 用于制备咪唑并[1,2-b]哒嗪类化合物的中间体
WO2023166172A1 (en) 2022-03-04 2023-09-07 Leo Pharma A/S Small molecule modulators of il-17
KR20250023378A (ko) * 2022-05-19 2025-02-18 다이스 알파, 인크. 락탐 치환된 이미다조피리다진 il-17a 조정제 및 그의 용도
CN115806503B (zh) * 2022-12-02 2025-03-07 中国海洋大学 一种选择性组蛋白去乙酰化酶抑制剂及其制备方法和应用
TW202430165A (zh) 2022-12-02 2024-08-01 丹麥商理奧藥品公司 Il-17之小分子調節劑
CN121311483A (zh) * 2023-03-28 2026-01-09 詹森药业有限公司 含内酰胺的咪唑并哒嗪il-17抑制剂化合物
WO2024215597A1 (en) * 2023-04-11 2024-10-17 Dice Alpha, Inc. Substituted 6-imidazopyridazine il-17a modulators and uses thereof
WO2025202931A1 (en) 2024-03-27 2025-10-02 Janssen Pharmaceutica Nv Imidazopyridazine il-17 inhibitor compounds
WO2025247285A1 (zh) * 2024-05-28 2025-12-04 西藏海思科制药有限公司 一种可抑制il-17a的杂环化合物制备及其用途
WO2026080825A1 (en) * 2024-10-10 2026-04-16 Revolution Medicines, Inc. Synthesis of ras inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108473500A (zh) * 2015-11-18 2018-08-31 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα响应的调节剂的咪唑并哒嗪化合物
CN111601799A (zh) * 2018-01-15 2020-08-28 Ucb生物制药有限责任公司 作为Il-17调节剂的稠合咪唑衍生物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
EP2892899B1 (en) * 2012-09-06 2018-03-21 Bristol-Myers Squibb Company Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
WO2014066726A2 (en) 2012-10-26 2014-05-01 Ensemble Therapeutics Corporation Compounds for modulating il-17
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
JP2017523214A (ja) 2014-08-05 2017-08-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヘテロ環キナーゼ阻害剤
GB201709456D0 (en) 2017-06-14 2017-07-26 Ucb Biopharma Sprl Therapeutic agents
CN110511213B (zh) 2018-05-22 2021-10-19 成都先导药物开发股份有限公司 一种免疫调节剂
EP3599245A1 (en) 2018-07-27 2020-01-29 Dompé farmaceutici S.p.A. Il-17a binding polypeptides and medical uses thereof
GB201820165D0 (en) 2018-12-11 2019-01-23 Ucb Biopharma Sprl Therapeutic agents
GB201820166D0 (en) 2018-12-11 2019-01-23 Ucb Biopharma Sprl Therapeutic agents
GB201820316D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for IL-17
SG11202106444WA (en) 2018-12-19 2021-07-29 Leo Pharma As Amino-acid anilides as small molecule modulators of il-17
TWI752400B (zh) 2019-01-07 2022-01-11 美商美國禮來大藥廠 Il-17a抑制劑
CN113874080B (zh) 2019-02-06 2024-09-27 戴斯阿尔法公司 Il-17a调节剂及其用途
US20220162191A1 (en) 2019-03-08 2022-05-26 Leo Pharma A/S Small molecule modulators of il-17
GB201909190D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
GB201909194D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
GB201909191D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
WO2021027729A1 (zh) 2019-08-09 2021-02-18 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341429B (zh) 2019-08-09 2021-11-23 成都先导药物开发股份有限公司 一种免疫调节剂的中间体化合物
CN112341435B (zh) 2019-08-09 2021-10-22 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341441B (zh) 2019-08-09 2022-02-11 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341439B (zh) 2019-08-09 2022-02-15 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341446B (zh) 2019-08-09 2022-06-17 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341451B (zh) 2019-08-09 2022-06-17 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341442B (zh) 2019-08-09 2021-10-22 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341450B (zh) 2019-08-09 2022-05-17 成都先导药物开发股份有限公司 一种免疫调节剂
WO2021170631A1 (en) 2020-02-25 2021-09-02 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
WO2021170627A1 (en) 2020-02-25 2021-09-02 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
WO2021204800A1 (en) 2020-04-07 2021-10-14 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
WO2021204801A1 (en) 2020-04-07 2021-10-14 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
PE20230469A1 (es) * 2020-04-30 2023-03-14 Janssen Pharmaceutica Nv Imidazopiridazinas como moduladores de il-17
US20230167497A1 (en) * 2020-04-30 2023-06-01 Xiaohua Xue Methods of identifying modulators of the il-17 pathway

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108473500A (zh) * 2015-11-18 2018-08-31 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα响应的调节剂的咪唑并哒嗪化合物
CN111601799A (zh) * 2018-01-15 2020-08-28 Ucb生物制药有限责任公司 作为Il-17调节剂的稠合咪唑衍生物

Also Published As

Publication number Publication date
US11702422B2 (en) 2023-07-18
EP4143195C0 (en) 2025-05-21
MX2022013647A (es) 2023-02-01
IL297705A (en) 2022-12-01
JP7664947B2 (ja) 2025-04-18
PE20230469A1 (es) 2023-03-14
ECSP22091485A (es) 2022-12-30
US11691979B2 (en) 2023-07-04
JP2023524018A (ja) 2023-06-08
CA3181676A1 (en) 2021-11-04
US12024524B2 (en) 2024-07-02
CO2022017072A2 (es) 2022-12-09
EP4143195B1 (en) 2025-05-21
JOP20220284A1 (ar) 2022-10-30
US20220402922A1 (en) 2022-12-22
AU2021264528A1 (en) 2023-01-19
US20230357254A1 (en) 2023-11-09
KR20230019507A (ko) 2023-02-08
EP4143195A1 (en) 2023-03-08
ZA202212967B (en) 2024-06-26
US20230081548A1 (en) 2023-03-16
UY39188A (es) 2021-10-29
TW202208367A (zh) 2022-03-01
WO2021222404A1 (en) 2021-11-04
AR121959A1 (es) 2022-07-27
TWI874645B (zh) 2025-03-01
ES3036330T3 (en) 2025-09-17
BR112022021962A2 (pt) 2023-03-28
CN115884810A (zh) 2023-03-31

Similar Documents

Publication Publication Date Title
CN115884810B (zh) 作为il-17调节剂的咪唑并哒嗪
CN114466849B (zh) 作为isoqc和/或qc酶的抑制剂的n-取代的-3,4-(稠合5-环)-5-苯基-吡咯烷-2-酮化合物
JP2024009851A (ja) Ｐｄ－１／ｐｄ－ｌ１阻害剤
TWI547480B (zh) Ｃ型肝炎病毒抑制劑
EP3271357B1 (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
CN101534829A (zh) 丙型肝炎病毒抑制剂
CN105085429B (zh) 芳杂环类衍生物及其在药物上的应用
CN115867348B (zh) 作为il-17调节剂的咪唑并嘧啶
TW200934486A (en) Hepatitis C virus inhibitors
CN118119613A (zh) 作为il-17调节剂的苯并咪唑
WO2021218997A1 (zh) 取代的氮杂五元环类化合物及其在药物中的应用
CN113563245B (zh) 取代的吡咯烷类化合物及其在药物中的应用
CN118488953A (zh) 用作单酰基甘油脂肪酶抑制剂的双环杂环化合物
EA049631B1 (ru) Имидазопиридазины в качестве модуляторов il-17
CN118139859A (zh) 苯并咪唑和氮杂苯并咪唑il-17抑制剂化合物
CN118076606A (zh) 咪唑并哒嗪il-17抑制剂化合物
HK40097687A (zh) 用於治疗癌症的2-杂芳基-3-氧代-2 ,3-二氢哒嗪-4-甲酰胺
CN118317962A (zh) 咪唑并哒嗪il-17抑制剂化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant